Showing results (51-60 of 95) with videos related to
Sort By:
Pageof 10
Journal of Immunology (Baltimore, Md. : 1950)|February 9, 2005
A novel neurotoxoid vaccine prevents mucosal botulismRyoki Kobayashi, Tomoko Kohda, Kosuke Kataoka, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 4, 2006
Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin AMassimo Maddaloni, Herman F Staats, Dagmara Mierzejewska, et al.Proceedings of the National Academy of Sciences of the United States of America|March 1, 2006
Mucosal and systemic adjuvant activity of alphavirus replicon particlesJoseph M Thompson, Alan C Whitmore, Jennifer L Konopka, et al.Science Advances|January 8, 2019
MRGPR-mediated activation of local mast cells clears cutaneous bacterial infection and protects against reinfectionMohammad Arifuzzaman, Yuvon R Mobley, Hae Woong Choi, et al.Journal of Controlled Release : Official Journal of the Controlled Release Society|November 10, 2015
PEG modified liposomes containing CRX-601 adjuvant in combination with methylglycol chitosan enhance the murine sublingual immune response to influenza vaccinationHardeep S Oberoi, Yvonne M Yorgensen, Audrey Morasse, et al.The HUGO Journal|December 2, 2010
Genetic determinants of immune-response to a polysaccharide vaccine for typhoidPartha P Majumder, Herman F Staats, Neeta Sarkar-Roy, et al.Journal of Medicinal Chemistry|November 24, 2005
Doxazolidine, a proposed active metabolite of doxorubicin that cross-links DNAGlen C Post, Benjamin L Barthel, David J Burkhart, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|March 25, 2023
Evaluation of repRNA vaccine for induction and in utero transfer of maternal antibodies in a pregnant rabbit modelAmit P Khandhar, Chelsea D Landon, Jacob Archer, et al.Molecular Cancer Therapeutics|January 7, 2005
Doxorubicin-formaldehyde conjugates targeting alphavbeta3 integrinDavid J Burkhart, Brian T Kalet, Michael P Coleman, et al.Journal of Virology|November 16, 2004
Gender differences in human immunodeficiency virus type 1-specific CD8 responses in the reproductive tract and colon following nasal peptide priming and modified vaccinia virus Ankara boostingJames W Peacock, Sushila K Nordone, Shawn S Jackson, et al.Pageof 10